Compare Bristol-Myers Squibb Co (BMY) vs Ulta Beauty Inc (ULTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Ulta Beauty Inc — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while Ulta Beauty Inc trades at $469.56 (market cap $20.17B). The key difference: Bristol-Myers Squibb Co is far larger — about 5.8× Ulta Beauty Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Ulta Beauty Inc pays none. Which is the better fit depends on your goals.
| BMY | ULTA | |
|---|---|---|
Market Cap | $116.30B | $20.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $62.37 | $706.82 |
52-Week Low | $42.60 | $450.75 |
Enterprise Value | $152.24B | $22.25B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
ULTA trades at $473.33, up 0.88% today, with a bullish technical signal despite mixed moving averages. The company reported Q1 2026 EPS of $7.74, beating expectations, and maintains strong profitability with a 39.33% gross margin and 47.45% ROE. Recent news highlights international expansion and a partnership with Bath & Body Works, while analyst consensus remains strongly positive with a $623.73 price target.
ULTA presents a compelling investment case with robust fundamentals and growth initiatives, though risks include competitive pressures and potential margin compression. The stock's current valuation below analyst targets suggests upside potential, supported by strong loyalty program engagement and strategic expansions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Ulta Beauty Inc
With more than 1,300 stores and a partnership with Target, Ulta Beauty is the largest specialized beauty retailer in the U.S. The firm offers makeup (43% of 2021 sales), fragrances, skin care, and hair care products (20% of 2021 sales), and bath and body items. Ulta offers private-label products and merchandise from more than 500 vendors. It also offers salon services, including hair, makeup, skin, and brow services, in all stores. Most Ulta stores are approximately 10,000 square feet and are in suburban strip centers. Ulta was founded in 1990 and is based in Bolingbrook, Illinois.
Read more on ULTA →
